Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C), rAd5 env A, rAd5 env B, rAd5 env C, rAd5 gag-pol, Placebo Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 8
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 4 more

Conditions: Cancer
Interventions: ADHERE; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 21 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Jackson, Michigan • Port Huron, Michigan

Conditions: Hypertension, Renal Insufficiency, Chronic
Interventions: Clinical Decision Support System (CDSS), Clinic Decision Sup System + Pharmacist; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 542 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Amyotrophic Lateral Sclerosis ALS
Interventions: MTP-101C; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK1292263, GSK1292263 matching placebo, Sitagliptin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Phoenix, Arizona • Chula Vista, California • Miami, Florida + 4 more

Conditions: Febrile Infection, Anthrax
Interventions: TaqMan Bacillus anthracis Detection Kit; Device
Lead sponsor: MRI Global; Industry
Eligibility: 2 Years to 89 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Tarpon Springs, Florida • Fall River, Massachusetts • Franklin, Massachusetts

Conditions: HIV Infections
Interventions: MRKAd5 HIV-1 gag/pol/nef, MRKAd5 HIV-1 gag/pol/nef placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 13
States / cities: San Diego, California • San Francisco, California • Torrance, California + 7 more

Conditions: Alcohol Dependence
Interventions: Contingency Management, standard case management treatment; Behavioral
Lead sponsor: UConn Health; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions: Laboratory Biomarker Analysis, Questionnaire Administration, Smac Mimetic LCL161; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myocardial Infarction, Acute Coronary Syndrome
Interventions: high-sensitivity cardiac troponin testing; Diagnostic Test
Lead sponsor: Fred Apple; Other
Eligibility: 21 Years and older
Enrollment: 1,559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Advanced Solid Tumors
Interventions: ABT-348, ABT-348 and carboplatin, ABT-348 and docetaxel; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Chicago, Illinois • Houston, Texas

Conditions: Abscess
Interventions: Septra; Drug
Lead sponsor: 59th Medical Wing; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Lackland Air Force Base, Texas

Conditions: Hepatitis B, Chronic
Interventions: JNJ-73763989, Placebo for JNJ-73763989, JNJ-56136379, Placebo for JNJ-56136379, Nucleos(t)ide Analog (NA); Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 8
States / cities: Bakersfield, California • Los Angeles, California • San Clemente, California + 5 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Placebo, Sotagliflozin; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 793 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 63
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 55 more

Conditions: Breast Cancer, Ovarian Cancer
Interventions: Psilocybin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Aurora, Colorado

Conditions: Depression, Cancer, Stage III Breast Cancer, Stage II Breast Cancer, Stage I Breast Cancer, Stage III Prostate Cancer, Stage II Prostate Cancer, Stage I Prostate Cancer, Stage III Colorectal Cancer, Stage II Colorectal Cancer, Stage I Colorectal Cancer
Interventions: MINDSET, Enhanced Usual Care (EUC); Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Opioid-use Disorder, Chronic Pain
Interventions: Acceptance and commitment therapy, Valera Smartphone Application, Treatment as Usual; Behavioral · Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Ovarian Cancer, Non-small Cell Lung Cancer
Interventions: TUB-040, Bevacizumab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 13
States / cities: Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 10 more

Conditions: Advanced Solid Malignancies
Interventions: AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391, Trastuzumab Deruxtecan (T-DXd), Datopotamab Deruxtecan (Dato-DXd); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 11
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 7 more

Conditions: Prostatic Neoplasms
Interventions: Niraparib, Apalutamide, Abiraterone Acetate, Prednisone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: West Hollywood, California • Louisville, Kentucky • Portland, Oregon + 1 more

Conditions: Prevention
Interventions: Purchase Behavior - (Non-CBD ads), Purchase Behavior - (CBD ads); Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 79 Years
Enrollment: 460 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Prostate Cancer
Interventions: Prostate Biopsy, Focal Brachytherapy , Assessment of QOL; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 3
States / cities: New Hyde Park, New York • New York, New York • Houston, Texas

Conditions: Gross Motor Development Delay
Interventions: Parent Educational Program; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Advanced Solid Tumors
Interventions: FORX-428; Drug
Lead sponsor: FoRx Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Palo Alto, California • San Francisco, California • Grand Rapids, Michigan + 5 more

Search by objective public record fields.

Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults

An Intervention to Promote Oral Agent Adherence and Symptom Management: ADHERE

Evaluation of an Electronic CKD Clinical Decision Support System (CDSS) in Clinical Care

Intestinal Microbiome Transplant in ALS

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

Febrile Whole Blood Specimen Collection and Testing

Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection

Contingency Management for Chronic Recidivist Alcohol-Dependent Patients

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

MERITnI - Mindray-hs-cTnI Assay: Analytical and Clinical Evaluation for the Diagnosis and RIsk AssessmenT of Myocardial InfarctIon.

ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors

Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence

Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)

Randomized Trial of ACT and a Care Management App in Primary Care-based Buprenorphine Treatment

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

RCT-Consumer Perceptions of Cannabidiol (CBD) Health Claims

Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer

Education Program for Caregivers of Children With Gross Motor Delays

A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.